Literature DB >> 23453881

Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System.

Yenlik Zheteyeva1, Pedro L Moro, Xin Yue, Karen Broder.   

Abstract

OBJECTIVE: We characterized reports to the Vaccine Adverse Event (AE) Reporting System (VAERS) of pregnant women who received meningococcal polysaccharide-protein conjugate vaccine Menactra (MenACWY-D; Sanofi Pasteur Inc., Swiftwater, PA). STUDY
DESIGN: We searched VAERS for reports of pregnant women who received MenACWY-D from Jan. 1, 2005 through Dec. 31, 2011. We conducted clinical review of reports and available medical records.
RESULTS: Of 103 identified reports, 38 (36.7%) did not describe any AE. No maternal or infant deaths were reported. The most frequent pregnancy-specific AE was spontaneous abortion in 17 (16.5%) reports. Urinary tract infections and fever with vomiting were the most frequent nonpregnancy-specific AEs found in 4 (3.9%) and 3 (2.9%) reports, respectively. We identified 1 report with a major congenital anomaly (aqueductal stenosis and severe ventriculomegaly).
CONCLUSION: Our comprehensive review of reports to VAERS in pregnant women after MenACWY-D did not identify any concerning patterns in maternal, infant, or fetal outcomes.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23453881     DOI: 10.1016/j.ajog.2013.02.027

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  20 in total

1.  The National Vaccine Advisory Committee: reducing patient and provider barriers to maternal immunizations: approved by the National Vaccine Advisory Committee on June 11, 2014.

Authors: 
Journal:  Public Health Rep       Date:  2015 Jan-Feb       Impact factor: 2.792

Review 2.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

3.  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Authors:  Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil
Journal:  MMWR Recomm Rep       Date:  2020-09-25

4.  The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United States.

Authors:  Pedro L Moro; Michael M McNeil; Lakshmi Sukumaran; Karen R Broder
Journal:  Hum Vaccin Immunother       Date:  2015-09-17       Impact factor: 3.452

Review 5.  Maternal immunization.

Authors:  Helen Y Chu; Janet A Englund
Journal:  Clin Infect Dis       Date:  2014-05-05       Impact factor: 9.079

Review 6.  Current safety issues with quadrivalent meningococcal conjugate vaccines.

Authors:  Tanya R Myers; Michael M McNeil
Journal:  Hum Vaccin Immunother       Date:  2017-11-08       Impact factor: 3.452

Review 7.  Meningococcal vaccination in pregnancy.

Authors:  Bahaa Abu Raya; Manish Sadarangani
Journal:  Hum Vaccin Immunother       Date:  2018-03-21       Impact factor: 3.452

8.  Major Birth Defects after Vaccination Reported to the Vaccine Adverse Event Reporting System (VAERS), 1990 to 2014.

Authors:  Pedro L Moro; Janet Cragan; Paige Lewis; Lakshmi Sukumaran
Journal:  Birth Defects Res       Date:  2017-07-17       Impact factor: 2.344

Review 9.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

10.  Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review.

Authors:  Tracy A Becerra-Culqui; Lina S Sy; Zendi Solano; Hung Fu Tseng
Journal:  Hum Vaccin Immunother       Date:  2020-12-17       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.